RTTNews BiotechDoubao · 实盘不做把握 7/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:27:53·⟳ 抓取 20:30:25 +2m32s·⚡ 决策 10-08 20:32:06 +1m41s·19.1 天前
Scholar Rock 重新向 EMA 提交 apitegromab 欧盟上市申请，改用备选灌装厂
欧盟 MAA 重新提交是修复此前因第三方 CDMO GMP 问题导致撤件的程序性步骤，且核心资产已在美国获批，市场基本预期；催化兑现（CHMP 意见）远在 2027 年上半年，短线无正期望，盘前股价微跌印证缺乏重定价动力。
📄 原文RTTNews Biotech↗ 原文
Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 Scholar Rock（SRRK.US）
欧盟 MAA 重新提交为修复撤件的程序性步骤、核心药已在美获批，CHMP 意见远在 2027H1，无近期预期差与催化，盘前微跌，风险收益不支持入场。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Scholar Rock 用备选灌装厂重新提交 apitegromab 的欧盟 MAA，属修复撤件的程序性里程碑，核心药已在美获批、CHMP 意见要等 2027H1，短线无预期差与催化，回避。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 medium ↗
消息传播链
- RTTNews 报道 Scholar Rock 重新提交 apitegromab 欧盟 MAA、改用备选灌装厂，预计 2027H1 CHMP 意见；盘前 SRRK 报 42.00 美元、跌 0.47%。市场反应:盘前微跌 0.47%，无明显方向性重定价
关键理由
- MAA 重新提交只将资产从「已撤回」推回「审评中」，并非获批，不产生近期销售。
- apitegromab 已获 FDA 批准（ISEMBYLD），欧盟进展属增量期权且兑现窗口在 2027H1，对当前估值弹性有限。
主要风险
- 若 CHMP 受理或审评时间表快于预期，可能带来阶段性情绪反弹。
- 备选灌装厂若再现 GMP 或供应问题，将再次拖延欧盟商业化。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
前次 MAA 因 Catalent Indiana GMP 不合规于 2026 年 8 月撤回，本次虽换厂但 CHMP 意见要到 2027H1，制造与监管时间风险仍在，削弱近期做多逻辑。
检索:apitegromab Europe MAA resubmission delay GMP Catalent risk 原文 ↗
先例如何影响了这次决策
对本次决策的影响:支持回避：无近期催化、无预期差，不提供入场依据。
方向:无高相似先例；但程序性 MAA 重新提交（非获批）结合资产已在美上市，通常不构成短线正向催化。
涨幅量级:缺乏可用于校准幅度的对齐先例，盘前 -0.47% 的实际反应支持幅度近零。
形态:无足够样本识别见光死模式；本次属低关注度监管步骤。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 87 ms
{"result": "search_processed_events:agent query=`apitegromab catalent indiana gmp withdrawal chmp | scholar rock apitegromab maa resubmission ema | srrk apitegromab european medicines agency resubmitted marketing authorisation`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent q - fetch_decision_experience 成功 stock_tools HTTP · 14 ms
{ - web_search 成功 doubao_search · 1,793 ms
豆包搜索结果（原始查询:Scholar Rock apitegromab ISEMBYLD FDA approval SMA 2026 Europe MAA timeline；API SearchType:web）
原文全文
展开原文 · 8,111 字
Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corporate News
Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab
By
RTTNews Staff Writer
✉
Published:
10/8/2026 8:27 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Scholar Rock (
SRRK
) has resubmitted the Marketing Authorisation Application for apitegromab for the treatment of children and adults with spinal muscular atrophy to the European Medicines Agency. The resubmitted apitegromab MAA includes Scholar Rock's alternate fill-finish facility in place of the Catalent Indiana fill-finish facility.
In August 2026, Scholar Rock informed the Committee for Medicinal Products for Human Use of the withdrawal of its previous MAA due to a lack of GMP compliance at the Catalent Indiana fill-finish facility. With the MAA resubmission, the company anticipates a CHMP opinion in the first half of 2027.
In pre-market trading on NasdaqGS, Scholar Rock shares are down 0.47 percent to $42.00.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
U.S. Stocks Under Pressure As Crude Oil Prices, Treasury Yields Surge
September 28, 2026 11:06 ET
U.S. Stocks Close Mostly Higher Amid Sharp Pullback By Crude Oil
September 25, 2026 16:27 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab
Scholar Rock's ISEMBYLD Wins FDA Approval As First Muscle-Targeted Therapy For SMA
Scholar Rock: FDA Grants Fast Track And Orphan Drug Designations To Apitegromab
Scholar Rock Says FDA Review Of Apitegromab BLA Continues; Approval Decision Expected By Sept. 30
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
No Dangerous Infectious Disease Detected Among Russia Lab Worker Contacts: WHO
October 07, 2026 08:48 ET
French, Japanese Chemists Win Nobel Prize For Solving Molecular Mystery
October 07, 2026 08:42 ET
'Rising Temperatures Mean Rising Danger In Pregnancy,' UNFCCC Chief Warns
October 07, 2026 08:19 ET
FAA To Accelerate Commercial Space Licensing
October 07, 2026 07:07 ET
NASA's SunRISE Mission To Launch No Earlier Than Mid-2027
October 07, 2026 06:52 ET
Christa Pike 'conscious And Speaking' After Failed Execution, Her Lawyers Say
October 07, 2026 06:49 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corporate News
Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab
By
RTTNews Staff Writer
✉
Published:
10/8/2026 8:27 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Scholar Rock (
SRRK
) has resubmitted the Marketing Authorisation Application for apitegromab for the treatment of children and adults with spinal muscular atrophy to the European Medicines Agency. The resubmitted apitegromab MAA includes Scholar Rock's alternate fill-finish facility in place of the Catalent Indiana fill-finish facility.
In August 2026, Scholar Rock informed the Committee for Medicinal Products for Human Use of the withdrawal of its previous MAA due to a lack of GMP compliance at the Catalent Indiana fill-finish facility. With the MAA resubmission, the company anticipates a CHMP opinion in the first half of 2027.
In pre-market trading on NasdaqGS, Scholar Rock shares are down 0.47 percent to $42.00.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
U.S. Stocks Under Pressure As Crude Oil Prices, Treasury Yields Surge
September 28, 2026 11:06 ET
U.S. Stocks Close Mostly Higher Amid Sharp Pullback By Crude Oil
September 25, 2026 16:27 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab
Scholar Rock's ISEMBYLD Wins FDA Approval As First Muscle-Targeted Therapy For SMA
Scholar Rock: FDA Grants Fast Track And Orphan Drug Designations To Apitegromab
Scholar Rock Says FDA Review Of Apitegromab BLA Continues; Approval Decision Expected By Sept. 30
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
No Dangerous Infectious Disease Detected Among Russia Lab Worker Contacts: WHO
October 07, 2026 08:48 ET
French, Japanese Chemists Win Nobel Prize For Solving Molecular Mystery
October 07, 2026 08:42 ET
'Rising Temperatures Mean Rising Danger In Pregnancy,' UNFCCC Chief Warns
October 07, 2026 08:19 ET
FAA To Accelerate Commercial Space Licensing
October 07, 2026 07:07 ET
NASA's SunRISE Mission To Launch No Earlier Than Mid-2027
October 07, 2026 06:52 ET
Christa Pike 'conscious And Speaking' After Failed Execution, Her Lawyers Say
October 07, 2026 06:49 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
5088ef2b34· 2026-10-08 20:32 · doubao / doubao-seed-evolving-latest-version · 策略包0c89ec5cee9e当前